Prediction of radiation pneumonitis using the effective α/β of lungs and heart in NSCLC patients treated with proton beam therapy
Locoregionally advanced stage non-small cell lung cancer (NSCLC) patients are commonly treated with concurrent radiochemotherapy (RCHT) and adjuvant immunotherapy [1,2]. Treatment intensification strategies in this patient group, e.g., dose escalation to the gross tumor volume (GTV) using stereotactic ablative radiotherapy (SABR) or positron-emission tomography (PET) guided dose-painting strategies, have thus far been unsuccessful, in part due to life-threatening toxicities, such as bleeding from major intrathoracic vessels or radiation pneumonitis (RP) [3,4]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 14, 2023 Category: Radiology Authors: Albrecht Wei ß, Steffen Löck, Ting Xu, Zhongxing Liao, Aswin L. Hoffmann, Esther G.C. Troost Tags: Original Article Source Type: research
Nine Years of Plan of the Day for Cervical Cancer: Plan Library Remains Effective Compared to Fully Online-Adaptive Techniques
External beam radiotherapy (EBRT) is an important part of the treatment of locally advanced cervical cancer (LACC) patients. Inter-fraction deformations in pelvic anatomy are known to vary widely in size within this patient group [1 –4], resulting in large inter-patient differences in target mobility. Consequently, population-based margins are undesirable as they disadvantage patients with low target mobility in terms of normal tissue sparing [5,6] or compromise the target coverage of the other patients, if chosen too small. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 13, 2023 Category: Radiology Authors: D.M.W. Reijtenbagh, J. Godart, J.J. Penninkhof, S. Quint, A.G. Zolnay, J.W.M. Mens, M.S. Hoogeman Tags: Original Article Source Type: research
Brain Metastasis tumor Segmentation and Detection using Deep Learning Algorithms: A Systematic Review and Meta-Analysis
Brain metastases (BMs), frequently observed in approximately one-fifth of adult cancer patients, emerge as a significant health concern and represent the most prevalent form of adult intracranial neoplasm, outpacing other forms of primary and secondary brain malignancies [1]. BMs often exist in tandem with metastases in other cranial compartments including the cranium, dura mater, and leptomeninges, thereby adding layers of complexity to clinical detection and subsequent treatment planning, as demonstrated by studies performed [2,3]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 13, 2023 Category: Radiology Authors: Ting-Wei Wang, Ming-Sheng Hsu, Wei-Kai Lee, Hung-Chuan Pan, Huai-Che Yang, Cheng-Chia Lee, Yu-Te Wu Tags: Original Article Source Type: research
Introduction of ultra-hypofractionation in breast cancer: implications for costs and resource use
Radiotherapy (RT)1 is a core component of the comprehensive management of breast cancer, from early-stage disease to metastasis, and is used in 87% of the cases [1]. Traditionally, the standard regimen for early breast cancer consisted of the delivery of a total dose of 50 Gy in 25 fractions of 2 Gy over 5 weeks (i.e., conventional fractionation, CF) [2]. Over the last few years, however, a series of landmark randomised controlled clinical trials investigated the efficacy of administering larger doses per fraction in a shorter period of time. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 11, 2023 Category: Radiology Authors: Sara-Lise Busschaert, Eva Kimpe, Kurt Barb é, Mark De Ridder, Koen Putman Tags: Original Article Source Type: research
Curative Carbon Ion Radiotherapy In A Head And Neck Mucosal Melanoma Series: Facing The Future Within Multidisciplinarity
Head and neck malignant mucosal melanomas (HNMM) are extremely rare and low-incidence tumors [1]. Despite recent advances in treatments, patients ’ Overall Survival (OS) remains poor (20%-40% at 5 years), with especially low outcomes for sinonasal subsites [2,3]. Due to the rarity and unpredictable clinical outcome, prospective studies are challenging, and no optimal treatment modality has been fully established yet. Radical resection with clear margin is the first option, usually followed by photon postoperative radiotherapy (PORT) to improve local/locoregional control [4,5]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 10, 2023 Category: Radiology Authors: Sara Ronchi, Alessandro Cicchetti, Maria Bonora, Rossana Ingargiola, Anna Maria Camarda, Stefania Russo, Sara Imparato, Paolo Castelnuovo, Ernesto Pasquini, Piero Nicolai, Mohssen Ansarin, Michele Del Vecchio, Marco Benazzo, Ester Orlandi, Barbara Vischio Tags: Original Article Source Type: research
Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses
Head and neck squamous cell cancer (HNSCC) accounts for approximately 800,000 cases and 400,000 deaths annually worldwide [1]. The standard of care for locally-advanced disease for oral cavity, oropharynx, hypopharynx, and larynx subsites is a multimodality treatment with permutations of radiation therapy (RT), chemotherapy (CT), and surgery, in function of tumor localization. Treatment sequelae in these highly functional zones may significantly affect quality of life; and despite optimal treatment, mortality remains high. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 10, 2023 Category: Radiology Authors: Elaine LIMKIN, Pierre BLANCHARD, Benjamin LACAS, Jean BOURHIS, Mahesh PARMAR, Lisa LICITRA, Quynh-Thu LE, Sue YOM, Catherine FORTPIED, Johannes LANGENDIJK, Jan B VERMORKEN, Jacques BERNIER, Jens OVERGAARD, Jonathan HARRIS, Jean-Pierre PIGNON, Anne AUPERIN Tags: Original Article Source Type: research
External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts
Chemoradiotherapy plays a key role in the curative treatment of esophageal cancer (EC), either in neo-adjuvant (nCRT) or definitive (dCRT) setting. The oncological outcome of these patients has improved significantly by the introduction of nCRT [1], and is expected to improve further with the introduction of immune therapy [2]. With improved survival, the prevention of treatment related complications is increasingly important for EC survivors. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 8, 2023 Category: Radiology Authors: M. Berb ée, C.T. Muijs, F.E.M. Voncken, L.S. Wee, M. Sosef, L. Etten van, J.W. Sandick van, F.A.R.M. Warmerdam, J.J. de Haan, E. Oldehinkel, J.M. Dieren van, L. Boersma, J.A. Langendijk, A. Schaaf van der, J.B. Reitsma, E. Schuit Tags: Original Article Source Type: research
PROton versus photon Therapy for Esophageal Cancer – a Trimodality strategy (PROTECT) NCT050555648
For patients diagnosed with locally advanced esophageal (EC) and gastroesophageal junction (EGC) cancers neo-adjuvant chemoradiotherapy (nCRT) followed by surgical resection[1] and adjuvant immunotherapy is considered standard of care[2]. These treatments often result in severe, acute, and late, heart- and lung complications[3 –7] which can be lethal[8]. Proton therapy (PT), in comparison with photon therapy (XT), allows for dose reductions to organs at risk (OAR) such as the heart and lungs due to the finite range of protons. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 5, 2023 Category: Radiology Authors: Mortensen HR, Populaire P, Hoffmann L, Moeller DS, Appelt A, Nafteux P, Muijs CT, Grau C, Hawkins MA, Troost EGC, Defraene G, Canters R, Clarke CS, Weber DC, Korevaar EW, Haustermans K, Nordsmark M, The PROTECT consortium Source Type: research
Mesenchymal stem cell-derived HGF attenuates radiation-induced senescence in salivary glands via compensatory proliferation
Head and neck cancer accounts for more than 550 000 cases annually worldwide [1] of with 70% of patients receiving radiotherapy. A common severe side effect of radiotherapy is hyposalivation and a consequent dry mouth sensation (xerostomia) which is often very difficult to treat [2]. The major cause of this side effect is the often unavoidable exposure of the salivary glands (SG) to radiation due to their position relative to the tumor within the radiotherapy treatment plan. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 3, 2023 Category: Radiology Authors: A.A. Soto-Gamez, M. van Es, E. Hageman, S.A. Serna-Salas, H. Moshage, M. Demaria, S. Pringle, R.P. Coppes Tags: Original Article Source Type: research
Outcomes Following Hypofractionated Radiation Therapy Alone for Surgically Unfit Early Esophageal Squamous Cell Carcinoma Patients; A Retrospective Single Center Analysis
Squamous cell carcinoma is the most common histologic type of esophageal cancer among most Asian countries, and comprises of 89.9% in Korea [1,2]. The rates of crude incidence and mortality by esophageal cancer were reported as 5.4 and 3.0 per 100,000 Koreans in the year of 2020 [3]. Although the treatment outcomes of esophageal squamous cell carcinoma (ESCC) is not satisfactory enough, the proportion of the patients who are diagnosed with early cT stage tumors has recently increased in Korea along with the routine endoscopic evaluation according to the National Cancer Screening Programme, which could be a promising aspect...
Source: Radiotherapy and Oncology - November 3, 2023 Category: Radiology Authors: Kangpyo Kim, Dongryul Oh, Jae Myoung Noh, Yang Won Min, Hong Kwan Kim, Yong Chan Ahn Tags: Original Article Source Type: research
Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation
Early-stage, lymph node-negative non-small cell lung cancer (NSCLC) is managed with surgical resection or stereotactic body radiation therapy (SBRT), which results in similar local control rates of approximately 90% [1 –6]. Despite effective eradication of the primary tumor, regional and distant recurrences remain and lead to progression-free survival (PFS) rates of only 60-80% two years post-treatment [3,5]. The role of adjuvant therapy following SBRT remains unclear, with considerations for treatment mostly ex trapolated from the surgical literature [7]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 3, 2023 Category: Radiology Authors: Maria Thor, Kelly Fitzgerald, Aditya Apte, Jung Hun Oh, Aditi Iyer, Otasowie Odiase, Saad Nadeem, Ellen D. Yorke, Jamie Chaft, Abraham J. Wu, Michael Offin, Charles B Simone II, Isabel Preeshagul, Daphna Y. Gelblum, Daniel Gomez, Joseph O. Deasy, Andreas Tags: Original Article Source Type: research
Evaluation and Analysis of Risk Factors of Hearing Impairment for Nasopharyngeal Carcinoma treated using Intensity-Modulated Radiotherapy
Nasopharyngeal carcinoma (NPC), initiating in nasopharyngeal epithelial cells, caused 133,354 new cases and 80,008 deaths globally in 2020, according to GLOBOCAN [1]. Although NPC accounted for only 7.2% of all cancers diagnosed in 2020, over 70% of new cases occurred in endemic areas. NPC has distinct geographical and ethnic distributions, particularly in north Africa, southern China, and south-east Asia, where the incidence rate standardized for age is 4 –25 cases per 100,000 people is much higher than that for Caucasians (about 1 in 100,000 [2]). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 3, 2023 Category: Radiology Authors: Lin Chen, Jing Li, Kunpeng Li, Jiang Hu, Qingjie Li, Chenglong Huang, Gaoyuan Wang, Na Liu, Linglong Tang Tags: Original Article Source Type: research
ESTRO clinical practice guideline: Stereotactic Body Radiotherapy for Spine metastases
Recent progress in diagnostics and treatment of metastatic cancer patients have improved survival substantially. These developments also affect local therapies, with treatment aims shifting from short-term palliation to long-term symptom or disease control. There is consequently a need to better define the value of stereotactic body radiotherapy (SBRT) for the treatment of spinal metastases. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 2, 2023 Category: Radiology Authors: M Guckenberger, N Andratschke, C Belka, D Bellut, F Cuccia, M Dahele, RS Guninski, M Josipovic, P Mancosu, G Minniti, M Niyazi, U Ricardi, P Munck af Rosenschold, A Sahgal, Y Tsang, WFAR Verbakel, F Alongi Source Type: research
Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model
Among breast cancer subtypes, triple-negative breast cancer (TNBC) has a relatively immunogenic tumor microenvironment (TME) with higher immune cell infiltration and PD-L1 expression compared to other subtypes, resulting in clinical benefits from immune checkpoint inhibitors (ICIs) in clinical trials[1 –4] Nevertheless, the overall response rates in these clinical trials were less than 25%, and additional strategies are needed. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 2, 2023 Category: Radiology Authors: Jun Yeong Song, Min Guk Han, Yoomin Kim, Min Ji Kim, Mi Hyun Kang, Seung Hyuck Jeon, In Ah Kim Tags: Original Article Source Type: research
Response to the letter to the editor by Maci à I Garau et al. regarding the article “ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma” by Niyazi et al
We wish to extend our gratitude to our esteemed colleagues, Maci à i Garau et al., for their insightful remarks on our paper. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - November 1, 2023 Category: Radiology Authors: Maximilian Niyazi, Martin Bendszus, Giuseppe Minniti Tags: Letter to the Editor Source Type: research
